Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 8, 2008 - Issue 2
Submit an article Journal homepage
176
Views
8
CrossRef citations to date
0
Altmetric
Reviews

Antigen-specific therapy of rheumatoid arthritis

Thomas E Ichim University of Western Ontario, Departments of Surgery, Pathology, Microbiology & Immunology, 339 Windermere Road, University Hospital C9-136, London, Ontario, N6A 5A5, Canada +1 519 663 2985; +1 519 663 3295; [email protected]; Medistem Laboratories, San Diego, CA, USA
,
Xiufen Zheng University of Western Ontario, Departments of Surgery, Pathology, Microbiology & Immunology, 339 Windermere Road, University Hospital C9-136, London, Ontario, N6A 5A5, Canada +1 519 663 2985; +1 519 663 3295; [email protected]
,
Motohiko Suzuki University of Western Ontario, Departments of Surgery, Pathology, Microbiology & Immunology, 339 Windermere Road, University Hospital C9-136, London, Ontario, N6A 5A5, Canada +1 519 663 2985; +1 519 663 3295; [email protected]
,
Norihiko Kubo University of Western Ontario, Departments of Surgery, Pathology, Microbiology & Immunology, 339 Windermere Road, University Hospital C9-136, London, Ontario, N6A 5A5, Canada +1 519 663 2985; +1 519 663 3295; [email protected]
,
Xusheng Zhang University of Western Ontario, Departments of Surgery, Pathology, Microbiology & Immunology, 339 Windermere Road, University Hospital C9-136, London, Ontario, N6A 5A5, Canada +1 519 663 2985; +1 519 663 3295; [email protected]
,
Lisa R Min University of Western Ontario, Departments of Surgery, Pathology, Microbiology & Immunology, 339 Windermere Road, University Hospital C9-136, London, Ontario, N6A 5A5, Canada +1 519 663 2985; +1 519 663 3295; [email protected]
,
Marianne E Beduhn University of Western Ontario, Departments of Surgery, Pathology, Microbiology & Immunology, 339 Windermere Road, University Hospital C9-136, London, Ontario, N6A 5A5, Canada +1 519 663 2985; +1 519 663 3295; [email protected]
,
Neil H Riordan Medistem Laboratories, San Diego, CA, USA
,
Robert D Inman University Health Network, Division of Rheumatology, Department of Medicine, Toronto Western Hospital, Toronto, Canada
&
Wei-Ping Min University of Western Ontario, Departments of Surgery, Pathology, Microbiology & Immunology, 339 Windermere Road, University Hospital C9-136, London, Ontario, N6A 5A5, Canada +1 519 663 2985; +1 519 663 3295; [email protected]
 show all
Pages 191-199 | Published online: 14 Jan 2008

Bibliography

  • Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31(3):315-24
  • Gaffo A, Saag KG, Curtis JR. Treatment of rheumatoid arthritis. Am J Health Syst Pharm 2006;63(24):2451-65
  • Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet 1999;354(9194):1932-9
  • Salliot C, Gossec L, Ruyssen-Witrand A, et al. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) 2007;46(2):327-34
  • Wallis RS. Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma. J Investig Dermatol Symp Proc 2007;12(1):16-21
  • Chadha T, Hernandez JE. Infliximab-related lupus and associated valvulitis: a case report and review of the literature. Arthritis Rheum 2006;55(1):163-6
  • Benucci M, Li Gobbi F, Fossi F, et al. Drug-induced lupus after treatment with infliximab in rheumatoid arthritis. J Clin Rheumatol 2005;11(1):47-9
  • Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2006;33(12):2398-408
  • Mackay IR, Rowley MJ. Autoimmune epitopes: autoepitopes. Autoimmun Rev 2004;3(7-8):487-92
  • Kotzin BL, Falta MT, Crawford F, et al. Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis. Proc Natl Acad Sci USA 2000;97(1):291-6
  • Yamada R, Suzuki A, Chang X, et al. Citrullinated proteins in rheumatoid arthritis. Front Biosci 2005;10:54-64
  • Massa M, Passalia M, Manzoni SM, et al. Differential recognition of heat-shock protein DNAJ-derived epitopes by effector and Treg cells leads to modulation of inflammation in juvenile idiopathic arthritis. Arthritis Rheum 2007;56(5):1648-57
  • Kamphuis S, Albani S, Prakken BJ. Heat-shock protein 60 as a tool for novel therapeutic strategies that target the induction of regulatory T cells in human arthritis. Expert Opin Biol Ther 2006;6(6):579-89
  • Fehr K. Autoimmune reactions and rheumatoid arthritis. Eur J Rheumatol Inflamm 1982;5(4):439-56
  • Golds EE, Stephen IB, Esdaile JM, et al. Lymphocyte transformation to connective tissue antigens in adult and juvenile rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, systemic lupus erythematosus, and a nonarthritic control population. Cell Immunol 1983;82(1):196-209
  • Fugger L, Rothbard JB, Sonderstrup-McDevitt G. Specificity of an HLA-DRB1*0401-restricted T cell response to type II collagen. Eur J Immunol 1996;26(4):928-33
  • Cook AD, Rowley MJ, Mackay IR, et al. Antibodies to type II collagen in early rheumatoid arthritis. Correlation with disease progression. Arthritis Rheum 1996;39(10):1720-7
  • Kim WU, Yoo WH, Park W, et al. IgG antibodies to type II collagen reflect inflammatory activity in patients with rheumatoid arthritis. J Rheumatol 2000;27(3):575-81
  • Kim WU, Cho ML, Jung YO, et al. Type II collagen autoimmunity in rheumatoid arthritis. Am J Med Sci 2004;327(4):202-11
  • Smolen JS, Steiner G. Are autoantibodies active players or epiphenomena? Curr Opin Rheumatol 1998;10(3):201-6
  • Lundberg K, Nijenhuis S, Vossenaar ER, et al. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther 2005;7(3):R458-67
  • von Delwig A, Altmann DM, Isaacs JD, et al. The impact of glycosylation on HLA-DR1-restricted T cell recognition of type II collagen in a mouse model. Arthritis Rheum 2006;54(2):482-91
  • Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med 1977;146(3):857-68
  • Wooley PH. Immunotherapy in collagen-induced arthritis: past, present, and future. Am J Med Sci 2004;327(4):217-26
  • Williams RO. Collagen-induced arthritis in mice: a major role for tumor necrosis factor-alpha. Methods Mol Biol 2007;361:265-84
  • Bendele AM, Chlipala ES, Scherrer J, et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000;43(12):2648-59
  • Allen JB, Wong HL, Costa GL, et al. Suppression of monocyte function and differential regulation of IL-1 and IL-1ra by IL-4 contribute to resolution of experimental arthritis. J Immunol 1993;151(8):4344-51
  • Faria AM, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol 2006;13(2-4):143-57
  • Fukaura H, Kent SC, Pietrusewicz MJ, et al. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 1996;98(1):70-7
  • Inobe J, Slavin AJ, Komagata Y, et al. IL-4 is a differentiation factor for transforming growth factor-beta secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. Eur J Immunol 1998;28(9):2780-90
  • Baggi F, Andreetta F, Caspani E, et al. Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis. J Clin Invest 1999;104(9):1287-95
  • Im SH, Barchan D, Fuchs S, et al. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. J Clin Invest 1999;104(12):1723-30
  • Hultkrantz S, Ostman S, Telemo E. Induction of antigen-specific regulatory T cells in the liver-draining celiac lymph node following oral antigen administration. Immunology 2005;116(3):362-72
  • Tsuji NM, Mizumachi K, Kurisaki J. Antigen-specific, CD4+CD25+ regulatory T cell clones induced in Peyer's patches. Int Immunol 2003;15(4):525-34
  • Battaglia M, Gianfrani C, Gregori S, et al. IL-10-producing T regulatory type 1 cells and oral tolerance. Ann NY Acad Sci 2004;1029:142-53
  • Sun J, Alison Stalls M, Thompson KL, et al. Cell cycle block in anergic T cells during tolerance induction. Cell Immunol 2003;225(1):33-41
  • Nagler-Anderson C, Bober LA, Robinson ME, et al. Suppression of type II collagen-induced arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci USA 1986;83(19):7443-6
  • Zhang ZY, Lee CS, Lider O, et al. Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen. J Immunol 1990;145(8):2489-93
  • Thompson HS, Harper N, Bevan DJ, et al. Suppression of collagen induced arthritis by oral administration of type II collagen: changes in immune and arthritic responses mediated by active peripheral suppression. Autoimmunity 1993;16(3):189-99
  • Yoshino S. Antigen-induced arthritis in rats is suppressed by the inducing antigen administered orally before, but not after immunization. Cell Immunol 1995;163(1):55-8
  • Kim WU, Lee WK, Ryoo JW, et al. Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: a novel treatment strategy for induction of oral tolerance. Arthritis Rheum 2002;46(4):1109-20
  • Margalit M, Israeli E, Shibolet O, et al. A double-blind clinical trial for treatment of Crohn's disease by oral administration of alequel, a mixture of autologous colon-extracted proteins: a patient-tailored approach. Am J Gastroenterol 2006;101(3):561-8
  • Hyun JG, Barrett TA. Oral tolerance therapy in inflammatory bowel disease. Am J Gastroenterol 2006;101(3):569-71
  • Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117(4):761-9
  • Hafler DA, Kent SC, Pietrusewicz MJ, et al. Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis. Ann NY Acad Sci 1997;835:120-31
  • Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993;259(5099):1321-4
  • McKown KM, Carbone LD, Bustillo J, et al. Induction of immune tolerance to human type I collagen in patients with systemic sclerosis by oral administration of bovine type I collagen. Arthritis Rheum 2000;43(5):1054-61
  • Lee S, Scherberg N, DeGroot LJ. Induction of oral tolerance in human autoimmune thyroid disease. Thyroid 1998;8(3):229-34
  • Hauselmann HJ, Caravatti M, Seifert B, et al. Can collagen type II sustain a methotrexate-induced therapeutic effect in patients with long-standing rheumatoid arthritis? A double-blind, randomized trial. Br J Rheumatol 1998;37(10):1110-7
  • Kraus TA, Toy L, Chan L, et al. Failure to induce oral tolerance in Crohn's and ulcerative colitis patients: possible genetic risk. Ann NY Acad Sci 2004;1029:225-38
  • Suzuki A, Van de Water J, Gershwin ME, et al. Oral tolerance and pyruvate dehydrogenase in patients with primary biliary cirrhosis. Dev Immunol 2002;9(2):55-61
  • Pozzilli P, Pitocco D, Visalli N, et al. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia 2000;43(8):1000-4
  • Wildner G, Thurau SR. Oral tolerance in autoimmune uveitis. Dev Ophthalmol 1999;31:67-76
  • Sai P, Rivereau AS, Granier C, et al. Immunization of non-obese diabetic (NOD) mice with glutamic acid decarboxylase-derived peptide 524-543 reduces cyclophosphamide-accelerated diabetes. Clin Exp Immunol 1996;105(2):330-7
  • Ramiya VK, Shang XZ, Pharis PG, et al. Antigen based therapies to prevent diabetes in NOD mice. J Autoimmun 1996;9(3):349-56
  • Sakurai Y, Brand DD, Tang B, et al. Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice. Arthritis Res Ther 2006;8(5):R150
  • Dai YD, Carayanniotis G, Sercarz E. Antigen processing by autoreactive B cells promotes determinant spreading. Cell Mol Immunol 2005;2(3):169-75
  • Routsias JG, Vlachoyiannopoulos PG, Tzioufas AG. Autoantibodies to intracellular autoantigens and their B-cell epitopes: molecular probes to study the autoimmune response. Crit Rev Clin Lab Sci 2006;43(3):203-48
  • Pal R, Deshmukh US, Ohyama Y, et al. Evidence for multiple shared antigenic determinants within Ro60 and other lupus-related ribonucleoprotein autoantigens in human autoimmune responses. J Immunol 2005;175(11):7669-77
  • Warren KG, Catz I, Ferenczi LZ, et al. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol 2006;13(8):887-95
  • Darlington CL. NBI-5788 neurocrine. Curr Opin Investig Drugs 2005;6(7):747-51
  • Spack EG. Antigen-specific therapies for the treatment of multiple sclerosis: a clinical trial update. Expert Opin Investig Drugs 1997;6(11):1715-27
  • Myers LK, Stuart JM, Seyer JM, et al. Identification of an immunosuppressive epitope of type II collagen that confers protection against collagen-induced arthritis. J Exp Med 1989;170(6):1999-2010
  • Prakken BJ, Roord S, Ronaghy A, et al. Heat shock protein 60 and adjuvant arthritis: a model for T cell regulation in human arthritis. Springer Semin Immunopathol 2003;25(1):47-63
  • Puga Yung GL, Le TD, Roord S, et al. Heat shock proteins (HSP) for immunotherapy of rheumatoid arthritis (RA). Inflamm Res 2003;52(11):443-51
  • Kamphuis S, Kuis W, de Jager W, et al. Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet 2005;366(9479):50-6
  • Sloan-Lancaster J, Shaw AS, Rothbard JB, et al. Partial T cell signaling: altered phospho-zeta and lack of zap70 recruitment in APL-induced T cell anergy. Cell 1994;79(5):913-22
  • Verhoef A, Lamb JR. Threshold signaling of human Th0 cells in activation and anergy: modulation of effector function by altered TCR ligand. J Immunol 2000;164(11):6034-40
  • Min SY, Park KS, Cho ML, et al. Antigen-induced, tolerogenic CD11c+, CD11b+ dendritic cells are abundant in Peyer's patches during the induction of oral tolerance to type II collagen and suppress experimental collagen-induced arthritis. Arthritis Rheum 2006;54(3):887-98
  • Mowat AM. Basic mechanisms and clinical implications of oral tolerance. Curr Opin Gastroenterol 1999;15(6):546-56
  • Zhang Y, Chung Y, Bishop C, et al. Regulation of T cell activation and tolerance by PDL2. Proc Natl Acad Sci USA 2006;103(31):11695-700
  • Fleeton M, Contractor N, Leon F, et al. Involvement of dendritic cell subsets in the induction of oral tolerance and immunity. Ann NY Acad Sci 2004;1029:60-5
  • Drexler HG, Quentmeier H. FLT3: receptor and ligand. Growth Factors 2004;22(2):71-3
  • Williamson E, Westrich GM, Viney JL. Modulating dendritic cells to optimize mucosal immunization protocols. J Immunol 1999;163(7):3668-75
  • Onai N, Obata-Onai A, Schmid MA, et al. Flt3 in regulation of type I interferon-producing cell and dendritic cell development. Ann NY Acad Sci 2007;1106:253-61
  • Inaba K, Metlay JP, Crowley MT, et al. Dendritic cells as antigen presenting cells in vivo. Int Rev Immunol 1990;6(2-3):197-206
  • Harzstark AL, Small EJ. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). Expert Opin Biol Ther 2007;7(8):1275-80
  • Min WP, Zhou D, Ichim TE, et al. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol 2003;170(3):1304-12
  • Enk AH. DCs and cytokines cooperate for the induction of tregs. Ernst Schering Res Found Workshop 2006;6:97-106
  • Corinti S, Albanesi C, La Sala A, et al. Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol 2001;166(7):4312-8
  • Selenko-Gebauer N, Majdic O, Szekeres A, et al. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol 2003;170(7):3637-44
  • Ureta G, Osorio F, Morales J, et al. Generation of dendritic cells with regulatory properties. Transplant Proc 2007;39(3):633-7
  • Lutz MB, Suri RM, Niimi M, et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol 2000;30(7):1813-22
  • Yang J, Bernier SM, Ichim TE, et al. LF15-0195 generates tolerogenic dendritic cells by suppression of NF-kappaB signaling through inhibition of IKK activity. J Leuk Biol 2003;74(3):438-47
  • Xia X, Zhang X, Huang X, et al. LF 15-0195 generates synergistic tolerance by promoting formation of CD4+CD25+CTLA4+ T cells. J Immunother 2005;28(6):560-3
  • Hill JA, Ichim TE, Kusznieruk KP, et al. Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol 2003;171(2):691-6
  • Li M, Zhang X, Zheng X, et al. Immune modulation and tolerance induction by RelB-silenced dendritic cells through RNA interference. J Immunol 2007;178(9):5480-7
  • Popov I, Li M, Zheng X, et al. Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res Ther 2006;8(5):R141
  • Kaiser J. Clinical research. Death prompts a review of gene therapy vector. Science 2007;317(5838):580
  • Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004;200(3):277-85
  • Valencia X, Stephens G, Goldbach-Mansky R, et al. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006;108(1):253-61
  • Toubi E, Kessel A, Mahmudov Z, et al. Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab. Ann NY Acad Sci 2005;1051:506-14
  • Chatenoud L. CD3 antibody treatment stimulates the functional capability of regulatory T cells. Novartis Found Symp 2003;252:279-86; discussion 286-90

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.